Integrative Cancer Genomics: Drivers, Pathways and Drugs

综合癌症基因组学：驱动因素、途径和药物

• 批准号: 8534063
• 负责人: Dana Pe'er
• 金额: $ 35.81万
• 依托单位: COLUMBIA UNIV NEW YORK MORNINGSIDE
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-01 至 2017-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8534063
• 关键词: AKT inhibition; Algorithms; Antineoplastic Agents; Automobile Driving; Biological Assay; Breast Cancer Cell; Cancer cell line; Candidate Disease Gene; Cell physiology; Cells; Collaborations; Colon Carcinoma; Computer Simulation; Computing Methodologies; DNA copy number; Data; Diagnostic; Drug resistance; Feedback; Foundations; Gene Expression; Genes; Genetic; Genetic Determinism; Genetic Transcription; Genome; Genomics; Gleevec; Glioblastoma; Grant; Growth; Heterogeneity; Individual; Link; Machine Learning; Malignant Neoplasms; Malignant neoplasm of ovary; Measures; Memorial Sloan-Kettering Cancer Center; Methods; MicroRNAs; Modeling; Molecular; Mutation; Nature; Oncogenes; Pathway interactions; Patients; Pharmaceutical Preparations; Phenotype; Play; Proteins; Proto-Oncogene Proteins c-akt; Publishing; RNA Interference; Resistance; Roche brand of trastuzumab; Role; Solutions; The Cancer Genome Atlas; Therapeutic; Time; Validation; Work; arm; base; cancer cell; cancer genome; cancer genomics; cancer therapy; computerized tools; follow-up; human FRAP1 protein; improved; malignant breast neoplasm; melanoma; novel; response; success; tool; tumor; tumor progression; tumorigenesis; tumorigenic

DESCRIPTION (provided by applicant): The emergence of cancer genomics, combined with increased understanding of the molecular basis of oncogenesis, has stimulated hope that treatment will improve by becoming more targeted and individualized in nature. Cancer genomics studies established a number of critical cancer genes, leading to a number of successful targeted therapies (e.g. Gleevec, Herceptin and Plexxikon). Despite these successes, most cancers do not have a targeted therapy and when one exists, response is highly variable, even among patients that share the targeted mutation and tumor type. To move cancer into the era of personalized therapies, it becomes important to identify the alterations driving tumor progression in each tumor, determine the network that links these aberrations, and identify factors that predict sensitivity to targeted therapies. As projects such as The Cancer Genome Atlas (TCGA) amass cancer cell genomes at a breathtaking pace, a staggering genetic complexity is revealed. To interpret cancer genomes, a key computational challenge is to separate the wheat from the chaff and define both what are the key alterations likely to be functionally driving cancer and then, after defining such genes, begin to identify mechanisms of action and therapeutic implications. Leveraging components from our published methods, CONEXIC (Akavia et.al Cell 2010) and LirNet (Lee et.al, PLOS Gen 2009), we will develop machine-learning algorithms that integrate cancer genomic data to do just that. We will apply the methods we develop to melanoma, glioblastoma, ovarian, breast and colon cancer and experimentally follow up on our computational findings, towards a better understanding of each of these deadly cancers. The approaches developed in this grant will accelerate discovery to rapidly extract the maximal value from modern genomic studies and help carry cancer genomics from the diagnostic to the therapeutic realm.

描述(申请人提供)：癌症基因组学的出现，加上对肿瘤发生的分子基础的了解的增加，激发了人们的希望，即治疗将通过变得更加有针对性和个体化而得到改善。癌症基因组学研究确定了一些关键的癌症基因，导致了一些成功的靶向治疗(例如格列卫、赫赛汀和Plexxikon)。尽管取得了这些成功，但大多数癌症没有靶向治疗，即使有靶向突变和肿瘤类型的患者，反应也非常不同。为了将癌症带入个性化治疗的时代，重要的是确定每个肿瘤中驱动肿瘤进展的变化，确定连接这些异常的网络，并确定预测靶向治疗敏感性的因素。随着癌症基因组图谱(TCGA)等项目以惊人的速度积累癌细胞基因组，一个惊人的遗传复杂性被揭示出来。为了解释癌症基因组，一个关键的计算挑战是将小麦和谷壳分开，并定义可能在功能上导致癌症的关键变化，然后在定义这些基因后，开始识别作用机制和治疗意义。利用我们公布的方法CONEXIC(Akavia et.al Cell 2010)和LirNet(Lee et.al，PLOS Gen 2009)中的组件，我们将开发集成癌症基因组数据的机器学习算法来实现这一点。我们将把我们开发的方法应用于黑色素瘤、胶质母细胞瘤、卵巢癌、乳腺癌和结肠癌，并通过实验跟踪我们的计算结果，以更好地了解这些致命的癌症。这笔赠款中开发的方法将加速发现，迅速从现代基因组研究中提取最大价值，并帮助将癌症基因组学从诊断领域带入治疗领域。